IAM
TEVA icon

Ion Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Ion Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,603
Closed -$718K – 41
2023
Q1 		$718K Hold
12,603
– – 0.08% 32
2022
Q4 		$1.49M Buy
+12,603
New +$110K 0.2% 31
2017
Q4 		– Sell
-2,200
Closed -$339K – 16
2017
Q3 		$339K Buy
+2,200
New +$49.5K 0.1% 16

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Ion Asset Management's TEVA Position: Q3 2025 in Review

Ion Asset Management reduced its Teva Pharmaceuticals (TEVA) stake by 86% in Q3 2025, selling an estimated $577M and leaving 5,510,000 shares worth $111M. The position accounts for 12.22% of the portfolio, ranked #1.

Ion Asset Management first reported a position in TEVA in Q4 2014 and has held it in 24 quarters since. The position peaked at $808M in Q4 2024. 550 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Ion Asset Management held 5,510,000 shares of Teva Pharmaceuticals worth $111M as of Q3 2025.
  • Ion Asset Management sold 32,837,875 Teva Pharmaceuticals shares in Q3 2025, an estimated $577M.
  • Teva Pharmaceuticals made up 12.22% of Ion Asset Management's portfolio in Q3 2025, its #1 holding.
  • Ion Asset Management first reported a position in Teva Pharmaceuticals in Q4 2014 and has held it in 24 quarters since.
  • Ion Asset Management's Teva Pharmaceuticals position peaked at $808M in Q4 2024.
  • 550 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Ion Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.